Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity
Open Access
- 17 February 2009
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 9 (1) , 4
- https://doi.org/10.1186/1475-2867-9-4
Abstract
The prototypical antiprogestin mifepristone exhibits potent growth inhibition activity towards ovarian cancer cells in vitro and in vivo. The aim of this research was to establish whether mifepristone is capable of inhibiting cell proliferation and inducing apoptotic cell death regardless of the degree of sensitivity ovarian cancer cells exhibit to cisplatin.This publication has 66 references indexed in Scilit:
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Mifepristone Inhibits Ovarian Cancer Cell GrowthIn vitroandIn vivoClinical Cancer Research, 2007
- Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cellsBritish Journal of Cancer, 2007
- The p53 family in differentiation and tumorigenesisNature Reviews Cancer, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsPublished by Elsevier ,2006
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- p53 modulation of the DNA damage responseJournal of Cellular Biochemistry, 2006
- Diagnosis and Management of Epithelial Ovarian CancerObstetrics & Gynecology, 2006
- Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005
- Modulation of Janus kinase 2 by p53 in ovarian cancer cellsBiochemical and Biophysical Research Communications, 2004